drugset / Trial / NCT03823404
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled study that assessed the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate Alzheimer's disease (AD) dementia.
Timeline
- Start
- 2019-03-28
- Primary completion
- 2022-01-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATUZAGINSTAT | Small molecule | 40 mg | Oral |
| Subject | ATUZAGINSTAT | Small molecule | 80 mg | Oral |